Next Article in Journal
Role and Redirection of IgE against Cancer
Next Article in Special Issue
In Vivo Secretion of Bispecific Antibodies Recruiting Lymphocytic Effector Cells
Previous Article in Journal / Special Issue
Immunotherapy of B-Cell Lymphoma with an Engineered Bispecific Antibody Targeting CD19 and CD5
Article Menu

Export Article

Open AccessReview
Antibodies 2013, 2(2), 353-370; doi:10.3390/antib2020353

The Development of Bispecific Hexavalent Antibodies as a Novel Class of DOCK-AND-LOCKTM (DNLTM) Complexes

Immunomedics, Inc., Morris Plains, NJ 07950, USA
IBC Pharmaceutical, Inc., Morris Plains, NJ 07950, USA
Garden State Cancer Center, Center of Immunology and Molecular Medicine, Morris Plains, NJ 07950, USA
Authors to whom correspondence should be addressed.
Received: 1 March 2013 / Revised: 9 May 2013 / Accepted: 13 May 2013 / Published: 23 May 2013
(This article belongs to the Special Issue Bispecific Antibodies for Dual Targeting Strategies)
View Full-Text   |   Download PDF [532 KB, uploaded 23 May 2013]   |  


The DOCK-AND-LOCKTM (DNLTM) method provides a modular approach to develop multivalent, multifunctional complexes of defined structures, of which bispecific hexavalent antibodies (bsHexAbs) are prominent examples with potential applications in targeted therapy for malignant, autoimmune, and infectious diseases. Currently, bsHexAbs are constructed by derivatizing a divalent IgG, at the carboxyl termini of either the heavy chain (the CH3-format) or the light chain (the Ck-format), to contain two stabilized dimers of Fab having a different specificity from the IgG. In this review, we briefly outline the features of the DNLTM method and describe key aspects of bsHexAbs examined with diverse preclinical studies, which include binding affinity to target cells, induction of signaling pathways, effector functions, serum stability, pharmacokinetics, and antitumor activity in human tumor xenograft models. Our findings favor the selection of the CK- over the CH3-format for further exploration of bsHexAbs in clinical trials. View Full-Text
Keywords: DNLTM; bispecific; hexavalent; conjugation; site-specific; antibodies; cancer DNLTM; bispecific; hexavalent; conjugation; site-specific; antibodies; cancer
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Chang, C.-H.; Rossi, E.A.; Wang, Y.; Cardillo, T.M.; Goldenberg, D.M. The Development of Bispecific Hexavalent Antibodies as a Novel Class of DOCK-AND-LOCKTM (DNLTM) Complexes. Antibodies 2013, 2, 353-370.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top